Detection of telomerase status by semiquantitative and in situ assays, and by real-time reverse transcription-polymerase chain reaction (telomerase reverse transcriptase) assay in bladder carcinomas

BJU International

Volumn 91, Issue 6, 2003, Pages 567-572

  Longchampt, E ^a,b   Lebret, T ^b   Molinie, V ^b   Bieche, I ^a   Botto, H ^b   Lidereau, R ^a  

^a INSERM   (France)

^b FOCH HOSPITAL   (France)

Author keywords

Bladder carcinoma; ELISA based TRAP assay; hTERT; Real time quantitative RT PCR; Telomerase

Indexed keywords

MESSENGER RNA; RNA DIRECTED DNA POLYMERASE;

ARTICLE; BLADDER CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TELOMERIC REPEAT AMPLIFICATION PROTOCOL;

DNA-BINDING PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TELOMERASE; TELOMERE-BINDING PROTEINS; URINARY BLADDER NEOPLASMS;

EID: 0038366917     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2003.04117.x     Document Type: Article

References (26)

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000. Cancer incidence, mortality and prevalence worldwide. Version 1.0. IARC Cancerbase No. 5. Lyon: IARC Press, 2001
2. Gelmini S, Crisci A, Salvadori B, Pazzagli M, Selli C, Orlando C. Comparison of telomerase activity in bladder carcinoma and exfoliated cells collected in urine and bladder washings, using a quantitative assay. Clin Cancer Res 2000; 6: 2771-6
3. Kausch I, Böhle A. Molecular aspects of bladder cancer III. Prognostic markers of bladder cancer. Eur Urol 2002; 41: 15-29
4. Lebret T, Becette V, Hervé JM et al. Prognostic value of MIB-1 antibody labeling index to predict response to bacillus Calmette-Guérin therapy in a high-risk selected population of patients with stage T1 grade G3 bladder cancer. Eur Urol 2000; 37: 654-9
5. Mathon NF, Lloyd AC. Cell senescence and cancer. Nature 2001; 1: 203-13
6. Kim NW, Piatyszek MA, Prowse KR et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011-5
7. Lee DH, Yang SC, Hong SJ, Chung BH, Kim IY. Telomerase. a potential marker of bladder transitional cell carcinoma in bladder washes. Clin Cancer Res 1998; 4: 535-8
8. Heine B, Hummel M, Müller M, Heicappell R, Miller K, Stein H. Non-radioactive measurement of telomerase activity in human bladder cancer, bladder washings, and in urine. J Pathol 1998; 184: 71-6
9. Rahat MA, Lahat N, Gazawi H et al. Telomerase activity in patients with transitional cell carcinoma. A preliminary study. Cancer 1999; 85: 919-24
10. Lancelin F, Anidjar M, Vilette JM et al. Telomerase activity as a potential marker in preneoplastic bladder lesions. BJU Int 2000; 85: 526-31
11. De Kok JB, Schalken JA, Aalders TW, Ruers TJM, Willems HL, Swinkels DW. Quantitative measurement of telomerase reverse transcriptase (hTERT) mRNA in urothelial cell carcinomas. Int J Cancer 2000; 87: 217-20
12. Ito H, Kyo S, Kanaya T et al. Detection of human telomerase reverse transcriptase messenger RNA in voided urine samples as a useful diagnostic tool for bladder cancer. Clin Cancer Res 1998; 4: 2807-10
13. Hisatomi H, Nagao K, Kanamaru T, End H, Tomimatsu M, Hikiji K. Levels of telomerase catalytic subunit mRNA as a predictor of potential malignancy. Int J Oncol 1999; 14: 727-32
14. Ohyashiki K, Ohyashiki JH, Nishimaki J et al. Cytological detection of telomerase activity using an in situ telomeric repeat amplification protocol assay. Cancer Res 1997; 57: 2100-3
15. Mostofi FK, David C, Sesterhenn I. Histologic typing of urinary bladder tumors. World Health Organization. Berlin: Springer-Verlag, 1999
16. Bièche I, Noguès C, Paradis V et al. Quantification of hTERT gene expression in sporadic breast tumors with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res 2000; 6: 452-9
17. Müller M, Krause H, Heicappell R, Tischendorf J, Shay JW, Miller K. Comparison of human telomerase RNA and telomerase activity in urine for diagnosis of bladder cancer. Clin Cancer Res 1998; 4: 1949-54
18. Lin Y, Miyamoto H, Fujinami K et al. Telomerase activity in human bladder cancer. Clin Cancer Res 1996; 2: 929-32
19. Yoshida K, Sugino T, Tahara H et al. Telomerase activity in bladder carcinoma and its implication for noninvasive diagnosis by detection of exfoliated cancer cells in urine. Cancer 1997; 79: 362-9
20. Linn JF, Lango M, Halachmi S, Schoenberg MP, Sidransky D. Microsateltite analysis and telomerase activity in archived tissue and urine samples of bladder cancer patients. Int J Cancer 1997; 74: 625-9
21. Mayfield MP, Shah T, Flannigan GM, Hamilton Stewart PA, Bibby MC. Telomerase activity in malignant and benign bladder conditions. Int J Mol Med 1998; 1: 835-40
22. Hou M, Xu D, Björkholm M, Gruber A. Real-time quantitative telomeric repeat amplification protocol assay for the detection of telomerase activity. Clin Chem 2001; 47: 519-24
23. Wu Y-Y, Hruszkewycz AM, Delgado RM et al. Limitations on the quantitative determination of telomerase activity by the electrophoretic and ELISA based TRAP assays. Clin Chim Acta 2000; 293: 199-212
24. Suzuki T, Suzuki Y, Fujioka T. Expression of the catalytic subunit associated with telomerase gene in human urinary bladder cancer. J Urol 1999; 162: 2217-20
25. Dejmek A, Yahata N, Ohyashiki K et al. In situ telomerase activity in pleural effusions: a promising marker for malignancy. Diagn Cytopathol 2000; 24: 11-5
26. Ohyashiki K, Yahata N, Ohyashiki J et al. A combination of semiquantitative telomerase assay and in-cell telomerase activity measurement using exfoliated urothelial cells for detection of urothelial neoplasia. Cancer 1998; 83: 2554-60